Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling

Carcinogenesis

Volumn 30, Issue 7, 2009, Pages 1082-1088

  Inokuchi, Junichi ^a,b   Lau, Alice ^a   Tyson, Darren R ^a,c   Ornstein, David K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LIPOCORTIN 1; MESSENGER RNA; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN;

ACINAR CELL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL ASSAY; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEPLETION; PROTEIN SECRETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANNEXIN A1; AUTOCRINE COMMUNICATION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-6; MALE; PROSTATE; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 67650151006     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp078     Document Type: Article

References (53)

1. Gerke,V. et al. (2005) Annexins: Linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol., 6, 449-461.
2. Lim,L.H. et al. (2007) Annexin 1: The new face of an old molecule. FASEB J., 21, 968-975.
3. Paweletz,C.P. et al. (2000) Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res., 60, 6293-6297.
4. Kang,J.S. et al. (2002) Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin. Cancer Res., 8, 117-123.
5. Smitherman,A.B. et al. (2004) Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J. Urol., 171, 916-920.
6. Patton,K.T. et al. (2005) Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia. Histopathology, 47, 597-601.
7. Xin,W. et al. (2003) Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am. J. Pathol. 162, 255-261.
8. Kishimoto,T. (2005) Interleukin-6: From basic science to medicine-40 years in immunology. Annu. Rev. Immunol., 23, 1-21.
9. Hodge,D.R. et al. (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer, 41, 2502-2512.
10. Azare,J. et al. (2007) Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol. Cell. Biol., 27, 4444-4453.
11. Spiotto,M.T. et al. (2000) STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate, 42, 88-98.
12. Paule,B. et al. (2007) The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: New therapeutic approaches? World J. Urol., 25, 477-489.
13. Hong,D.S. et al. (2007) Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer, 110, 1911-1928.
14. Gao,S.P. et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest., 117, 3846-3856.
15. Grivennikov,S. et al. (2008) Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell, 13, 7-9.
16. Lieblein,J.C. et al. (2008) STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer, 8 302.
17. Culig,Z. et al. (2005) Interleukin-6 regulation of prostate cancer cell growth. J. Cell. Biochem., 95, 497-505.
18. Hobisch,A. et al. (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol., 191, 239-244.
19. Giri,D. et al. (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol., 159, 2159-2165.
20. Okamoto,M. et al. (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res., 57, 141-146.
21. Drachenberg,D.E. et al. (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41, 127-133.
22. Adler,H.L. et al. (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J. Urol., 161, 182-187.
23. Yang,Y.H. et al. (2006) Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1. J. Immunol., 177, 8148-8153.
24. Morris,J.F. et al. (2006) Lack of annexin 1 results in an increase in corticotroph number inmale but not female mice. J. Neuroendocrinol., 18, 835-846.
25. Warne,J.P. et al. (2006) Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am. J. Physiol. Endocrinol. Metab., 291, E1264-E1273.
26. Hsiang,C.H. et al. (2006) The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells. Prostate, 66, 1413-1424.
27. Tyson,D.R. et al. (2007) Culture requirements of prostatic epithelial cell lines for acinar morphogenesis and lumen formation in vitro: Role of extracellular calcium. Prostate, 67, 1601-1613.
28. Bello,D. et al. (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis, 18, 1215-1223.
29. Chung,T.D. et al. (1999) Characterization of the role of IL-6 in the progression of prostate cancer. Prostate, 38, 199-207.
30. Inokuchi,J. et al. (2009) Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells. Int. J. Cancer, 124, 68-74.
31. Gerke,V. et al. (2002) Annexins: From structure to function. Physiol. Rev., 82, 331-371.
32. Akira,S. et al. (1993) Interleukin-6 in biology and medicine. Adv. Immunol., 54, 1-78.
33. Sansone,P. et al. (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest., 117, 3988-4002.
34. Nelson,C.M. et al. (2006) Of extracellular matrix, scaffolds, and signaling: Tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol., 22, 287-309.
35. Fournier,M.V. et al. (2006) Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res., 66, 7095-7102.
36. Mailleux,A.A. et al. (2007) BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev. Cell, 12, 221-234.
37. Reginato,M.J. et al. (2003) Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol., 5, 733-740.
38. Mills,K.R. et al. (2004) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc. Natl Acad. Sci. USA, 101 3438-3443.
39. Itoh,M. et al. (2003) The organization of tight junctions in epithelia: Implications for mammary gland biology and breast tumorigenesis. J. Mammary Gland Biol. Neoplasia, 8, 449-462.
40. Liu,H. et al. (2004) Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J. Cell Biol., 164, 603-612.
41. Bissell,M.J. et al. (2003) Polarity determination in breast tissue: Desmosomal adhesion, myoepithelial cells, and laminin 1. Breast Cancer Res., 5, 117-119.
42. Streuli,C.H. et al. (1991) Control of mammary epithelial differentiation: Basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity. J Cell Biol., 115, 1383-1395.
43. Aggeler,J. et al. (1991) Cytodifferentiation of mouse mammary epithelial cells cultured on a reconstituted basement membrane reveals striking similarities to development in vivo. J. Cell Sci., 99 (Pt 2), 407-417.
44. Becker,C. et al. (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle, 4, 217-220.
45. Quinn,D.I. et al. (2005) Molecular markers of prostate cancer outcome. Eur. J. Cancer, 41, 858-887.
46. Catz,S.D. et al. (2003) BCL-2 in prostate cancer: A minireview. Apoptosis, 8, 29-37.
47. Cavarretta,I.T. et al. (2008) Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv. Exp. Med. Biol., 617, 547-555.
48. Krajewska,M. et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148, 1567-1576.
49. Evans,M.K. et al. (2007) Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene, 26, 1941-1948.
50. Kim,S. et al. (2001) Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: Specific interaction model. FEBS Lett., 489, 243-248.
51. Balsinde,J. et al. (2002) Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett., 531, 2-6.
52. Liu,X.H. et al. (2002) Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem. Biophys. Res. Commun., 290, 249-255.
53. Herbert,S.P. et al. (2007) The confluence-dependent interaction of cytosolic phospholipase A2-alpha with annexin A1 regulates endothelial cell prostaglandin E2 generation. J. Biol. Chem., 282, 34468-34478.